GeneMatrix Inc
GeneMatrix Inc. develops diagnostic products for various diseases in the field of molecular diagnostics. The company offers products for hepatitis B, hepatitis C, cervical cancer, sexually transmitted infections, respiratory infections, and gastrointestinal infections; vaccines for preventing various diseases; and new natural pharmaceutical materials for health enhancement and treatment. It also … Read more
GeneMatrix Inc (109820) - Net Assets
Latest net assets as of September 2025: ₩18.32 Billion KRW
Based on the latest financial reports, GeneMatrix Inc (109820) has net assets worth ₩18.32 Billion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩28.03 Billion) and total liabilities (₩9.72 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩18.32 Billion |
| % of Total Assets | 65.33% |
| Annual Growth Rate | 1.55% |
| 5-Year Change | -42.42% |
| 10-Year Change | 91.56% |
| Growth Volatility | 36.7 |
GeneMatrix Inc - Net Assets Trend (2011–2024)
This chart illustrates how GeneMatrix Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for GeneMatrix Inc (2011–2024)
The table below shows the annual net assets of GeneMatrix Inc from 2011 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩19.23 Billion | -16.94% |
| 2023-12-31 | ₩23.15 Billion | -4.29% |
| 2022-12-31 | ₩24.19 Billion | -25.17% |
| 2021-12-31 | ₩32.32 Billion | -3.21% |
| 2020-12-31 | ₩33.39 Billion | +118.98% |
| 2019-12-31 | ₩15.25 Billion | +40.76% |
| 2018-12-31 | ₩10.83 Billion | -2.04% |
| 2017-12-31 | ₩11.06 Billion | -11.41% |
| 2016-12-31 | ₩12.48 Billion | +24.37% |
| 2015-12-31 | ₩10.04 Billion | -15.57% |
| 2014-12-31 | ₩11.89 Billion | -6.98% |
| 2013-12-31 | ₩12.78 Billion | -8.18% |
| 2012-12-31 | ₩13.92 Billion | -11.57% |
| 2011-12-31 | ₩15.74 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to GeneMatrix Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2144663611000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | ₩10.20 Billion | 53.03% |
| Other Components | ₩30.48 Billion | 158.51% |
| Total Equity | ₩19.23 Billion | 100.00% |
GeneMatrix Inc Competitors by Market Cap
The table below lists competitors of GeneMatrix Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Earlyworks Co., Ltd. American Depositary Shares
NASDAQ:ELWS
|
$21.54 Million |
|
Habco Trans Maritima
JK:HATM
|
$21.55 Million |
|
Wotso
AU:WOT
|
$21.55 Million |
|
Anli International Co Ltd
TWO:5223
|
$21.55 Million |
|
577 Investment Corp
VN:NBB
|
$21.53 Million |
|
Copper Mountain Mining Corporation
PINK:CPPMF
|
$21.52 Million |
|
Ugint Co Ltd
KQ:195990
|
$21.50 Million |
|
Ulaslar Turizm Yatirimlari ve Dayanikli Tuketim Mallari Ticaret Pazarlama AS
IS:ULAS
|
$21.50 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in GeneMatrix Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 23,148,242,030 to 19,227,336,450, a change of -3,920,905,580 (-16.9%).
- Net loss of 3,748,057,580 reduced equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-3.75 Billion | -19.49% |
| Other Changes | ₩-172.85 Million | -0.9% |
| Total Change | ₩- | -16.94% |
Book Value vs Market Value Analysis
This analysis compares GeneMatrix Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.19x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 2.58x to 2.19x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩814.65 | ₩2105.00 | x |
| 2017-12-31 | ₩721.74 | ₩2105.00 | x |
| 2018-12-31 | ₩675.66 | ₩2105.00 | x |
| 2019-12-31 | ₩845.72 | ₩2105.00 | x |
| 2020-12-31 | ₩1672.63 | ₩2105.00 | x |
| 2021-12-31 | ₩1618.95 | ₩2105.00 | x |
| 2022-12-31 | ₩1211.46 | ₩2105.00 | x |
| 2023-12-31 | ₩1159.49 | ₩2105.00 | x |
| 2024-12-31 | ₩963.09 | ₩2105.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently GeneMatrix Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -19.49%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -37.41%
- • Asset Turnover: 0.35x
- • Equity Multiplier: 1.48x
- Recent ROE (-19.49%) is below the historical average (-13.76%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | -10.98% | -16.82% | 0.39x | 1.67x | ₩-2.15 Billion |
| 2015 | -23.28% | -38.01% | 0.26x | 2.40x | ₩-2.89 Billion |
| 2016 | -30.26% | -74.35% | 0.26x | 1.55x | ₩-5.03 Billion |
| 2017 | -13.29% | -28.32% | 0.29x | 1.60x | ₩-2.58 Billion |
| 2018 | -28.68% | -65.61% | 0.15x | 2.91x | ₩-4.19 Billion |
| 2019 | -8.96% | -27.06% | 0.18x | 1.87x | ₩-2.89 Billion |
| 2020 | 24.05% | 50.50% | 0.42x | 1.14x | ₩4.69 Billion |
| 2021 | -3.06% | -8.16% | 0.31x | 1.22x | ₩-4.22 Billion |
| 2022 | -33.54% | -72.33% | 0.35x | 1.32x | ₩-10.53 Billion |
| 2023 | -3.87% | -9.12% | 0.31x | 1.35x | ₩-3.21 Billion |
| 2024 | -19.49% | -37.41% | 0.35x | 1.48x | ₩-5.67 Billion |
Industry Comparison
This section compares GeneMatrix Inc's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $86,114,650,433
- Average return on equity (ROE) among peers: -15.11%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| GeneMatrix Inc (109820) | ₩18.32 Billion | -10.98% | 0.53x | $21.53 Million |
| NSN Co. Ltd (031860) | $102.59 Billion | 0.00% | 0.91x | $4.54 Million |
| JOONGANG DNM Co.Ltd (051980) | $24.46 Billion | -32.51% | 0.43x | $77.93 Million |
| Genoray Co. Ltd (122310) | $11.35 Billion | 17.59% | 1.51x | $24.43 Million |
| Green Cross Lab Cell Corporation (144510) | $457.79 Billion | -16.14% | 0.26x | $147.96 Million |
| Optipharm.CO.LTD (153710) | $25.14 Billion | -9.69% | 0.56x | $30.10 Million |
| Cytogen Inc (217330) | $48.58 Billion | -35.23% | 0.49x | $27.02 Million |
| U2Bio Co., Ltd. (221800) | $33.84 Billion | 38.88% | 0.51x | $84.13 Million |
| Gencurix Inc (229000) | $8.20 Billion | -110.48% | 0.13x | $21.11 Million |
| P&K Skin Research Center Co. Ltd (347740) | $63.07 Billion | 11.56% | 0.06x | $15.93 Million |